2023 ´ëÇѳ»ºÐºñ¿Ü°úÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2023-04-07
±³À°ÀÏÀÚ : 2023-04-07
±³À°Àå¼Ò : ¿©¼ö º£³×Ä¡¾Æ È£ÅÚ ÄÁº¥¼Ç·ë
±³À°ÁÖÁ¦ : 2023 ´ëÇѳ»ºÐºñ¿Ü°úÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñ¿Ü°úÇÐȸ(¸íĪº¯°æ 22.9.19 ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ)
´ã´çÀÚ : ±èÀº¿µ
¿¬¶ôó : 02-501-2988
À̸ÞÀÏ : kates1996@naver.com
±³À°Á¾·ù : ¿Ü°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª : Àü¶ó³²µµ
±³À°½Ã°£ : 8 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 150,000¿ø
ºñ°í Æò»ýȸ¿ø : 10¸¸¿ø,12¸¸¿ø(ÇöÀå)Á¤È¸¿ø : 10¸¸¿ø, 12¸¸¿ø(ÇöÀå)Àü°øÀÇ : 7¸¸¿ø, 9¸¸¿ø(ÇöÀå) °£È£»ç : 5¸¸¿ø, 7¸¸¿ø(ÇöÀå)ºñȸ¿ø : 13¸¸¿ø, 15¸¸¿ø(ÇöÀå)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-07 ÄÁº¥¼Ç·ë 13:00~13:30 1) Guidelines for the management of parathyroid disease ±è¼öÁø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-07 ÄÁº¥¼Ç·ë 13:30~14:00 2) Various surgical treatment options for parathyroid disease ¹Ú´Ù¿ø(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-07 ÄÁº¥¼Ç·ë 14:00~14:30 3) Follow up of parathyroid disease patients À̽ÃÈÆ(°¡ÃµÀÇ´ë ³»ºÐºñ´ë»ç³»°ú)
±³À°½Ã°£ 04-07 ÄÁº¥¼Ç·ë 14:30~15:00 1) Guidelines for adrenalectomy ±è±¤¼ø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-07 ÄÁº¥¼Ç·ë 15:00~15:30 2) HALS(hand assisted laparoscopic surgery) adrenalectomy, searching for indication Á¶Àç¿ø(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-07 ÄÁº¥¼Ç·ë 15:30~16:00 3) AVS(adrenal venus sampling)ÀÇ À¯¿ë¼º ÀÌÃÊ·Ï(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 04-07 16:00~16:20 Coffee Break ()
±³À°½Ã°£ 04-07 ÄÁº¥¼Ç·ë 16:20~16:40 1) Clinical application of computer aided diagnosis in thyroid imaging °ûÁø¿µ(¿¬¼¼ÀÇ´ë ¿µ»óÀÇÇаú)
±³À°½Ã°£ 04-07 ÄÁº¥¼Ç·ë 16:40~17:00 2) Digital pathology Á¤Âù±Ç(°¡Å縯ÀÇ´ë º´¸®°ú)
±³À°½Ã°£ 04-07 ÄÁº¥¼Ç·ë 17:00~17:20 3) AI in paper work °»óÈñ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-07 ÄÁº¥¼Ç·ë 17:20~17:40 4) Medical metaverse ¹Ú»óÁØ(¸ÞµðÄþÆÀÌÇÇ)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 13:00~13:10 OP-1-1. A multicenter, randomized controlled study of health-related quality of life by TSH suppression levels in thyroid lobectomy patients: An interim analysis of the master study ÀÌÀÚ°æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 13:10~13:20 OP-1-2. Randomized clinical trial of prophylactic central neck dissection in 2000 PTC patients with clinically negative nodal disease: An interim analysis a single institution ¹é±³¸²(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 13:20~13:30 OP-1-3. Risk factor in re-recurrence PTC after initial total thyroidectomy ¹Ú»óÃá(Àü³²ÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 13:30~13:40 OP-1-4. Determining surgery extent in unilateral papillary thyroid carcinoma based on intraoperative pathologic evaluation of the lymph node number and size ¹èÇý¸²(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 13:40~13:50 OP-1-5. The recurrence rate of isthmectomy in papillary thyroid carcinoma patients Á¤ÇѼÖ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 13:50~14:00 OP-1-6. Lymph node ratio predicts recurrence in papillary thyroid carcinoma with low lymph node yield ¾È¼ÖÁö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 14:00~14:10 OP-1-7. Comparision between s according to subtypes in papillary thyroid cancer ÀÌÁؼº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 14:10~14:20 OP-1-8. Retropharyngeal node metastasis papillary thyroid carcinoma °¼®¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 14:20~14:30 OP-1-9. Clinical significance of tumor size in gross extrathyroidal extension to strap muscles in differentiated thyroid carcinoma ¹ÚÁؼ±(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 14:30~14:40 OP-2-1. Robotic versus endoscopic transoral thyroidectomy in papillary thyroid cancer: A comparative analysis of surgical outcomes in 240 consecutive patients ÀÌÁØÈ£(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 14:40~14:50 OP-2-2. First experience of single port robotic areolar approach thyroidectomy (SPRA) ÀÌÁø¿í(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 14:50~15:00 OP-2-3. Clinical application of pectoralis nerve block II for flap dissection-related pain control after robotic transaxillary thyroidectomy: Preliminary results of a randomized controlled trial ±è±¤¼ø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 15:00~15:10 OP-2-4. Transoral endoscopic thyroidectomy vestibular approach(TOETVA), does this procedure increase the risk of surgical site infection? Àü¿µ»ê(´ë±¸±¸º´¿ø)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 15:10~15:20 OP-2-5. One-step single-port transaxillary robotic thyroidectomy with gas-insufflation À念¿ì(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 15:20~15:30 OP-2-6. Early muscular remodeling in patient with thyroid cancer after transaxillary robot-assisted surgery À±ÇõÁØ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 15:30~15:40 OP-2-7. Reduced-port robotic transperitoneal adrenalectomy(RPRTPA): The initial experience ±è¿ë¿±(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 15:40~15:50 OP-2-8. Analysis of risk factors to predict poor prognosis in oncocytic adrenocortical neoplasm(uncertain malignancy) patients ±èº´Ã¢(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 15:50~16:00 OP-2-9. Factors affecting steroid istration date after adrenalectomy with Cushing À̵¿±Ù(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 04-07 16:00~16:20 Coffee Break ()
±³À°½Ã°£ 04-07 Æ佺ŸȦ 16:20~16:45 ÀÏÂ÷¼º °í¾Ëµµ½ºÅ×·ÐÁõ ȯÀÚÀÇ Ä¡·á¹ÝÀÀÀ» ¿¹ÃøÇÒ ¼ö ÀÖ´Â ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸ Á¶Àç¿ø(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 16:45~17:05 WHO grading system¿¡ µû¸¥ °©»ó¼± ¼öÁú¾ÏÀÇ ¿¹ÈÄ ¹× º´¸®ÇÐÀû ºÐ¼® : ´Ù±â°ü¿¬±¸ ÀÌÃÊ·Ï(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 17:05~17:25 °©»ó¼±¾Ï¿¡¼ IGF2BP3 º¯ÀÌÀÇ ºóµµ ¹× ¿¹ÈÄÀÎÀÚ·Î½á ¿ªÇÒ ÃÖÁØ¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-07 Æ佺ŸȦ 17:25~17:50 Çмú»ó ¿¬±¸°á°ú º¸°í : °©»ó¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ °³¹ßÀ» À§ÇÑ cell-free DNA À¯È¿¼º Ž»ö ȲÇö¿í(ÀÌÈÀÇ´ë)